Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Ipamorelin vs CJC-1295 + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Ipamorelin has stronger documented evidence (Anecdotal + Phase 2) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Ipamorelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Ipamorelin

Anecdotal + Phase 2

CJC-1295 + Ipamorelin

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: injection site reactions. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Ipamorelin CJC-1295 + Ipamorelin
Class Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist GHRH analog + selective GHRP blend (GH-secretagogue stack)
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm).
Route SC injection SC injection
Half-life ~2 hrs CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs
Dosage (research) 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC) 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off
Evidence tier Anecdotal + Phase 2 Anecdotal + Animal Studies
Research depth 64 indexed (PubMed 42 · CT 3 · EPMC 19) 5 indexed (PubMed 0 · CT 0 · EPMC 5)
Availability Compounding Restricted Compounding Restricted
Reported risks Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Ipamorelin or CJC-1295 + Ipamorelin?

Ipamorelin has stronger documented evidence (Anecdotal + Phase 2) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Ipamorelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Ipamorelin and CJC-1295 + Ipamorelin?

Ipamorelin is classed as Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist; CJC-1295 + Ipamorelin is classed as GHRH analog + selective GHRP blend (GH-secretagogue stack). Reported mechanism: Ipamorelin, Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise; CJC-1295 + Ipamorelin, Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). Reported half-life: Ipamorelin, ~2 hrs; CJC-1295 + Ipamorelin, CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs. Routes in published studies: Ipamorelin, SC injection; CJC-1295 + Ipamorelin, SC injection.

Which has stronger evidence, Ipamorelin or CJC-1295 + Ipamorelin?

Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Ipamorelin is graded Anecdotal + Phase 2, with 9 cited sources on its reference page and 64 indexed studies. CJC-1295 + Ipamorelin is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 5 indexed studies.

Which is more accessible, Ipamorelin or CJC-1295 + Ipamorelin?

Neither Ipamorelin nor CJC-1295 + Ipamorelin is an FDA-approved drug. Catalog status: Ipamorelin, Compounding Restricted; CJC-1295 + Ipamorelin, Compounding Restricted. FDA lists Ipamorelin in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).

Are Ipamorelin and CJC-1295 + Ipamorelin ever combined?

Ipamorelin and CJC-1295 + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…